(Q43016566)

12 November 2017

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management (English)

1 reference

ESMO Guidelines Working Group

12 November 2017

venous thromboembolism

1 reference

based on heuristic

inferred from title

author

series ordinal

4

object named as

ESMO Guidelines Working Group

1 reference

12 November 2017

M Mandalà

1

1 reference

PubMed ID

20555096

12 November 2017

A Falanga

series ordinal

2

1 reference

PubMed ID

20555096

12 November 2017

F Roila

series ordinal

3

1 reference

12 November 2017

1 May 2010

1 reference

12 November 2017

1 reference

12 November 2017

21 Suppl 5

1 reference

12 November 2017

v274-6

1 reference

Deep vein thrombosis in cancer: the scale of the problem and approaches to management

12 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ199

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ199

1 reference

12 November 2017

1 reference

PubMed ID

20555096